Ceftiofur
Based on 4 publication(s) in Google Scholar
Ceftiofur is a cell wall synthesis inhibitor that targets bacterial penicillin-binding proteins (PBPs) and has anti-inflammatory effects in endotoxemia. Ceftiofur exerts bactericidal effects by inhibiting the synthesis of bacterial cell wall peptidoglycan, leading to bacterial cell lysis. Ceftiofur also inhibits the activation of NF-κB and MAPKs, thereby reducing the secretion of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.81%
- CAS No.: 80370-57-6
- Formule: C19H17N5O7S3
- Masse moléculaire:523.56
-
Stockage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
MAPK Compound Library
HY-L010
-
NF-κB Signaling Compound Library
HY-L014
-
Stem Cell Signaling Compound Library
HY-L017
-
FDA-Approved Drug Library
HY-L022
-
Anti-Aging Compound Library
HY-L034
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Antibacterial Compound Library
HY-L049
-
Pyroptosis Compound Library
HY-L059
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Anti-Obesity Compound Library
HY-L087
-
Angiogenesis-Related Compound Library
HY-L088
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Liver Cancer Compound Library
HY-L101
-
Antidepressant Compound Library
HY-L108
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Anti-Pulmonary Fibrosis Compound Library
HY-L125
-
Cancer Stem Cells Compound Library
HY-L135
-
Pain-Related Compound Library
HY-L139
-
Off-patent Drug Library
HY-L141
-
Mitochondrial Protection Compound Library
HY-L144
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Autoimmune Disease Compound Library
HY-L156
-
Cytokine Inhibitors Library
HY-L161
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Gastric Cancer Compound Library
HY-L184
-
Anti-Fibrosis Compound Library
HY-L185
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Animal Drug Library
HY-L218
-
FDA Kinase Inhibitor Library
HY-L230
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Ceftiofur
MoreVoir tous les produits spécifiques à Isoform Antibiotic
MoreVoir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
35.7 μM
Compound: Ceftiofur
|
Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins
Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins
|
[PMID: 23344796] |
Ceftiofur (1, 5, 10 mg/L; pretreatment for 1 h+LPS stimulation for 12 h) can significantly inhibit the secretion of TNF-α, IL-1β, and IL-6 in RAW 264.7 cells, but has no significant effect on the secretion of IL-10[2].
Ceftiofur (1, 5, 10 mg/L; pretreatment for 1 h+LPS stimulation for 30 min) can significantly inhibit the phosphorylation of ERK, JNK, and p38 and the nuclear translocation of NF-κB p65 in RAW 264.7 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:RAW 264.7 cells
-
Concentration:1, 5, 10 mg/L
-
Incubation Time:1 h pretreatment with Ceftiofur followed by 30 min LPS stimulation
-
Result:Dramatically decreased the phosphorylation levels of ERK, JNK, and p38 in Ceftiofur-treated cells compared to the LPS-treated control cells, while the total protein levels of MAPKs showed no change.
-
Cell Line:RAW 264.7 cells
-
Concentration:1, 5, 10 mg/L
-
Incubation Time:1 h pretreatment with Ceftiofur followed by 30 min LPS stimulation
-
Result:Nuclear translocation of NF-κB p65 induced by LPS was strongly inhibited in a dose-dependent manner in Ceftiofur-pretreated cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6 mice (18-20 g, 6-8 weeks old) with LPS-induced endotoxemia model[3]
-
Dosage:20 mg/kg Ceftiofur (dissolved in saline)
-
Administration:Subcutaneous injection, single dose, administered 1 h before or 0, 1, 4, 12 h after intraperitoneal injection of 30 mg/kg LPS.
-
Result:Pretreatment with 20 mg/kg Ceftiofur 1 h before LPS challenge significantly increased the survival rate of mice (70% survival at 144 h vs. 0% in LPS control group).
When administered 0 or 1 h after LPS injection, Ceftiofur still provided significant protection, but protection decreased when delayed to 4 h and was absent at 12 h.
Plasma levels of TNF-α, IL-1β, and IL-6 in Ceftiofur-pretreated mice were significantly lower than those in the LPS control group at specific time points (1 h for TNF-α, 3 h for IL-6, 12 h for IL-1β), while IL-10 levels were significantly higher at 1 h after LPS challenge.
Chemical Information
-
CAS No. 80370-57-6
-
Appearance Solid
-
Masse moléculaire 523.56
-
Formule C19H17N5O7S3
-
Color White to off-white
-
SMILES
O=C(C(N12)=C(CSC(C3=CC=CO3)=O)CS[C@]2([H])[C@H](NC(/C(C4=CSC(N)=N4)=N\OC)=O)C1=O)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis. [Abstract]2020 Apr 14;11(1):1792. PMID: 32286289 -
Mol Syst Biol
2022 Sep;18(9):e11081. PMID: 36065847 -
Microorganisms
Isolation, Antimicrobial Susceptibility, and Genotypes of Three Pasteurellaeae Species Prevalent on Pig Farms in China Between 2021 and 2023. [Abstract]2025 Apr 18;13(4):938. PMID: 40284774 -
Vet Microbiol
Discovery of the tigecycline resistance gene cluster tmexCD3-toprJ1 in Pasteurella multocida strains isolated from pigs in China. [Abstract]2024 May:292:110046. PMID: 38471428
Solvant et solubilité
DMSO : 100 mg/mL (191.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.78 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (281 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Korean - KR (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Salmon SA, et al. In vitro activity of Ceftiofur and its primary metabolite, desfuroylCeftiofur, against organisms of veterinary importance. J Vet Diagn Invest. 1996 Jul;8(3):332-6. [Content Brief]
[2]. Ci X, et al. Ceftiofur impairs pro-inflammatory cytokine secretion through the inhibition of the activation of NF-kappaB and MAPK. Biochem Biophys Res Commun. 2008 Jul 18;372(1):73-7. [Content Brief]
[3]. Ci X, et al. Ceftiofur regulates LPS-induced production of cytokines and improves LPS-induced survival rate in mice. Inflammation. 2008 Dec;31(6):422-7. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9100 mL | 9.5500 mL | 19.1000 mL | 47.7500 mL |
| 5 mM | 0.3820 mL | 1.9100 mL | 3.8200 mL | 9.5500 mL | |
| 10 mM | 0.1910 mL | 0.9550 mL | 1.9100 mL | 4.7750 mL | |
| 15 mM | 0.1273 mL | 0.6367 mL | 1.2733 mL | 3.1833 mL | |
| 20 mM | 0.0955 mL | 0.4775 mL | 0.9550 mL | 2.3875 mL | |
| 25 mM | 0.0764 mL | 0.3820 mL | 0.7640 mL | 1.9100 mL | |
| 30 mM | 0.0637 mL | 0.3183 mL | 0.6367 mL | 1.5917 mL | |
| 40 mM | 0.0478 mL | 0.2388 mL | 0.4775 mL | 1.1938 mL | |
| 50 mM | 0.0382 mL | 0.1910 mL | 0.3820 mL | 0.9550 mL | |
| 60 mM | 0.0318 mL | 0.1592 mL | 0.3183 mL | 0.7958 mL | |
| 80 mM | 0.0239 mL | 0.1194 mL | 0.2388 mL | 0.5969 mL | |
| 100 mM | 0.0191 mL | 0.0955 mL | 0.1910 mL | 0.4775 mL |
Ceftiofur Related Classifications
HY-N7102 Related Classifications
Powered by Bioz